Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

This Phase II trial is testing ivonescimab, a new drug that combines two types of cancer-fighting mechanisms, in patients with advanced clear cell kidney cancer (renal cell carcinoma) who have already received prior treatment including immunotherapy. **You may be eligible if...** - You have confirmed advanced or metastatic clear cell kidney cancer - You have already received at least one prior treatment including a PD-1/PD-L1 immunotherapy drug - Your disease has progressed (gotten worse) after your last treatment - You are 18 or older with adequate organ function **You may NOT be eligible if...** - Your cancer has spread to the brain (unless stable and treated) - You have active autoimmune disease requiring treatment - You have not had prior systemic treatment - You have serious heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.